Despite remarkable progress in understanding the molecular basis of C1 inhibitor (C1INH)
deficiency (see article by Wagenaar-Bos and Hack elsewhere in this issue) and the
mechanism of swelling in hereditary angioedema (HAE) (see article by Davis elsewhere
in this issue), the pharmacologic options available for the treatment of HAE in the
United States have remained virtually unchanged over the past 40 years [
1
,
2
]. Prophylactic use of alpha-alkylated androgens or anti-fibrinolytic agents are generally
successful in decreasing the number and severity of angioedema attacks; however, these
medications are associated with significant adverse effects and do not successfully
address the treatment of acute attacks. Taken together, these problems indicate a
significant unmet need for improved treatment options of HAE in the United States.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Immunology and Allergy ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 years' clinical experience.Acta Med Scand Suppl. 1966; 448: 1-46
- Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema).Ann Intern Med. 1960; 53: 739-745
- A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1- esterase.Am J Med. 1963; 35: 37-44
- Hereditary angioneurotic edema. II. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein.J Allergy. 1962; 33: 330-341
- Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema—evidence of a functionally critical level of C1-inhibitor concentration.Complement. 1984; 1: 147-159
- Hereditary angioedema: a decade of management with stanozolol.J Allergy Clin Immunol. 1987; 80: 855-860
- Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma.Lancet. 1969; 1: 326-330
- Treatment of acute attacks of hereditary angioedema with C1-Inhibitor concentrate.Ann Allergy. 1980; 44: 299-301
- Replacement therapy in hereditary angioedema. Successful treatment of acute episodes of angioedema with partly purified C1 inhibitor.N Engl J Med. 1980; 302: 542-546
- Treatment of hereditary angioedema.Klin Wochenschr. 1978; 56: 819-823
- C1 INH concentrate in the therapy of hereditary angioedema.Allergy. 1983; 38: 81-84
- Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema.Arch Intern Med. 2001; 161: 714-718
- C1-inhibitor: an anti-inflammatory reagent with therapeutic potential.Expert Opin Pharmacother. 2001; 2: 1073-1083
- Hereditary angio-oedema: treatment with C1 esterase inhibitor concentrate.J R Soc Med. 1984; 77: 1046-1048
- Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients.Medicine (Baltimore). 1992; 71: 206-215
- Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency.Arch Intern Med. 2003; 163: 1229-1235
- A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema.Transfusion. 1998; 38: 540-549
- How do we treat patients with hereditary angioedema?.Transfus Apher Sci. 2003; 29: 221-227
- Hereditary angioedema: new findings concerning symptoms, affected organs, and course.Am J Med. 2006; 119: 267-274
- Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.N Engl J Med. 1996; 334: 1630-1634
- Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a.Transfus Apheresis Sci. 2003; 29 (review.jean.de.serres@aventis.com): 247-254
US HAE Association. C1-inhibitor (C1INH) personal importation. Available at: http://www.hereditaryangioedema.com/import.html. Accessed October 20, 2006.
- Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.J Allergy Clin Immunol. 1989; 83: 677-682
- Hereditary angioedema managed with low-dose danazol and C1 esterase inhibitor concentrate: a case report.J Obstet Gynaecol Can. 2006; 28: 27-31
- Successful off-pump coronary artery bypass graft surgery in a patient with hereditary angioedema.J Cardiothorac Vasc Anesth. 2002; 16: 473-476
- Hereditary angioedema: uncomplicated maxillofacial surgery using short-term C1 inhibitor replacement therapy.Int Arch Allergy Immunol. 1993; 101: 107-112
- Tonsillectomy in a patient with hereditary angioedema after prophylaxis with C1 inhibitor concentrate.Ann Allergy. 1994; 73: 435-438
- [The use of a C1-inhibior concentrate for short-term preoperative prophylaxis in two patients with hereditary angioedema.].Anaesthesist. 1996; 45 ([in German]): 626-630
- Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies.JCI. 1989; 83: 1794-1799
- Hereditary angioedema with normal C1-inhibitor activity in women.Lancet. 2000; 356: 213-217
- Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency.J Allergy Clin Immunol. 2006; 117: 904-908
- Recent advances in the use of C1 inhibitor as a therapeutic agent.Mol Immunol. 2003; 40: 155-158
- C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema Strong correlation with the severity of disease in C1-INH concentrate naive patients.Mol Immunol. 2007; 44: 1454-1460
- Nanofiltration of plasma-derived biopharmaceutical products.Haemophilia. 2003; 9: 24-37
- N- and O-glycans of recombinant human C1 inhibitor expressed in the milk of transgenic rabbits.Glycobiology. 2004; 14: 51-64
- A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema.J Allergy Clin Immunol. 2005; 116: 876-883
- [Recombinant human C1-inhibitor is effective in the treatment of acute attacks of hereditary angioedema–case report].Przegl Lek. 2005; 62 ([in Polish]): 317-320
- C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.Pharmacol Rev. 2000; 52: 91-112
- Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion.J Immunol. 2003; 171: 4786-4791
- C1 inhibitor: molecular and clinical aspects.Springer Semin Immunopathol. 2005; 27: 286-298
- C1-esterase inhibitor in ischemia and reperfusion.Immunobiology. 2002; 205: 552-562
- C1-inhibitor and transplantation.Immunobiology. 2002; 205: 534-541
- C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide.J Immunol. 2003; 171: 2594-2601
- C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation.Neurobiol Dis. 2005; 19: 10-17
- Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema.N Engl J Med. 1983; 308: 1050-1054
- Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.JCI. 1986; 78: 567-575
- Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization.JCI. 1969; 48: 642-653
- Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma.Trans Assoc Am Physicians. 1977; 40: 174-183
- Detection of active kallikein in induced blister fluids of hereditary angioedema patients.J Exp Med. 1980; 152: 742-747
- Generation of bradykinin during incubation of hereditary angioedema plasma.Mol Immunol. 1983; 19: 1365
- Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin.J Allergy Clin Immunol. 1983; 72: 54-60
- Use of a kallikrein inhibitor in the treatment of urticaria and hereditary angioneurotic edema.Acta Derm Venereol. 1969; 49: 37-44
- Anaphylactic shock secondary to initial Trasylol administration.Am J Gastroenterol. 1971; 56: 542-544
- Anaphylactic reaction to aprotinin.Lancet. 1976; 2 ([letter]): 48-49
- DX-88 and HAE: a developmental perspective.Transfus Apheresis Sci. 2003; 29: 255-258
- Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor.J Clin Invest. 2002; 109: 1057-1063
- Selective inhibition of plasma kallikrein protects brain from reperfusion injury.J Pharmacol Exp Ther. 2006; 318: 849-854
- Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema.J Allergy Clin Immunol. 2006; 117: 476-477
- Reply: anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema.J Allergy Clin Immunol. 2006; 117: 477
- A new generation of bradykinin antagonists.Immunopharmacology. 1996; 33: 51-60
- Kinin antagonists: design and activities.J Cardiovasc Pharmacol. 1990; 15: S69-S74
- Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.Br J Pharmacol. 1991; 102: 769-773
- Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma.Immunopharmacology. 1996; 33: 238-242
- The kallikrein-kinin system: current and future pharmacological targets.J Pharmacol Sci. 2005; 99: 6-38
Article info
Footnotes
This work was supported in part by Grants AI36220 and RR00833 from the National Institutes of Health.
Identification
Copyright
© 2006 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
